

# Effect of an Elixir on the Absorption of Vitamin B<sub>12</sub> by Healthy Young and Old Subjects\*

By BACON F. CHOW, PH.D., ANDREW HORONICK, B.S., AND KUNIO OKUDA, M.D.

THE ABSORPTION of orally administered vitamin B<sub>12</sub>, even by healthy people, is poor.<sup>1</sup> In patients suffering from pernicious anemia,<sup>2,3</sup> or in those with complete gastrectomy,<sup>4</sup> vitamin B<sub>12</sub> absorption is negligible. The oral coadministration of normal gastric juice or intrinsic factor preparations can increase the vitamin B<sub>12</sub> absorption in the latter groups; however, whether such agents can also increase absorption in clinically healthy subjects has not yet been demonstrated by any systematic study. On the contrary, it has been found that an excessive dose of the usual intrinsic factor preparations may inhibit the absorption of vitamin B<sub>12</sub> by normal rats,<sup>5</sup> by young, healthy humans,<sup>6</sup> and by gastrectomized subjects.<sup>4</sup> However, such data need not support the hypothesis that intrinsic factor, *per se*, is inhibitory. It has been demonstrated that highly purified preparations, or those prepared from sources without inhibitory substances, may actually enhance absorption.<sup>6</sup> This paper reports on several experiments designed to evaluate the ability of an elixir containing vitamin B<sub>12</sub>, other vitamins, and lipotropic substances† (hereinafter referred to as the "elixir" with vitamin B<sub>12</sub>) to

enhance vitamin B<sub>12</sub> absorption in both normal subjects and those suffering from pernicious anemia.

## METHOD

### *Medications Used*

The following medications were used in these studies: commercial vitamin capsules containing all known vitamins and minerals except vitamin B<sub>12</sub>,‡ capsules containing 100 µg of vitamin B<sub>12</sub>; solutions containing either 50 µg of radioactive (Co<sup>60</sup>) vitamin B<sub>12</sub> or 1000 µg of regular vitamin B<sub>12</sub>; and the "elixir" containing vitamin B<sub>12</sub>. One teaspoonful (5 ml) of the "elixir" with vitamin B<sub>12</sub> contains the following ingredients: vitamin B<sub>12</sub> (crystalline) 8.34 µg; riboflavin, 0.6 mg; niacinamide, 7.0 mg; pyridoxine, 2.0 mg; betaine, anhydrous, 700.0 mg; choline dihydrogen citrate, 150.0 mg; inositol, 150.0 mg; ferric pyrophosphate, 35.0 mg; caffeine citrate, 1 grain (65 mg); and alcohol, 15 per cent.

### *I. Studies of Vitamin B<sub>12</sub> Serum Levels*

A preliminary study was conducted in an old people's home by assaying the serum vitamin B<sub>12</sub> levels of 21 elderly patients (65 years or older) who had been receiving the "elixir" with vitamin B<sub>12</sub> (one teaspoon three times a day) for three months, and comparing the vitamin B<sub>12</sub> serum levels of these patients with those of 139 patients who had not received this treatment (Fig. 1).

The results of the preliminary study prompted us to conduct a second one on 60 healthy patients at a different home for the

---

From the Department of Biochemistry, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Md., and The Institute of Geriatrics of the Daughters of Jacob, Bronx, N. Y.

The authors acknowledge with thanks the grants-in-aid and material supplies from Smith, Kline & French Laboratories, Atomic Energy Commission No. AT-30-1203, The National Vitamin Foundation, Merck & Company, Inc., and the Lederle Laboratories.

\* Not presented at the Symposium.

† Liptril®, Smith, Kline & French Laboratories, Philadelphia, Pa.

‡ Gevral, Lederle Laboratories, Pearl River, N. Y.

aged. All of the patients chosen had vitamin B<sub>12</sub> serum levels of less than 175 μg per ml. They were randomly divided into two groups of 30 patients each. Group A received a daily

serum levels of all groups were compared (Fig. 2).

A third study was then conducted on another 40 elderly patients with vitamin B<sub>12</sub>




Fig. 1. Results of first serum level study. The cross-hatching in the columns denotes the magnitude of two standard deviations. The dividing line between the cross-hatching and the dotted portion immediately above it is the average value of the vitamin B<sub>12</sub> serum level.

capsule containing all known vitamins and minerals *except* vitamin B<sub>12</sub>; Group B received a capsule containing 100 μg of vitamin B<sub>12</sub>, in addition to the capsule received by Group A. Serum levels<sup>7</sup> were determined at frequent intervals for seven months. At the end of this period all but 16 patients (8 from Group A and 8 from Group B) were dropped from the experiment because they had either failed to follow the regimen faithfully, or because they were unwilling to submit to the laboratory procedures. At the beginning of the eighth month, four of the eight patients remaining in Group B were given 15 ml of the "elixir" with vitamin B<sub>12</sub> once a day (equal to a daily vitamin B<sub>12</sub> dose; 25 μg). The remaining four patients continued to receive 100 μg of vitamin B<sub>12</sub> a day. The blood




Fig. 2. Results of second serum level study.




Fig. 3. Results of third serum level study.

serum levels of less than 175  $\mu\text{g}$  per ml. Once daily, 20 of them (Group A) received a capsule containing 100  $\mu\text{g}$  of vitamin B<sub>12</sub>. The other 20 (Group B) received 15 ml of the "elixir" with vitamin B<sub>12</sub> (daily B<sub>12</sub> dose; 25  $\mu\text{g}$ ). Blood specimens were taken at frequent intervals. After four months of treatment all but 13 patients (7 from Group A; 6 from Group B) had dropped from the experiment. A comparison of results in these 13 patients is given in Figure 3.

## II. Urinary Excretion Studies

*Method of Assay:* The complete details of the urinary excretion test are published elsewhere.<sup>8</sup> Briefly, the method was as follows: 10 ml of an aqueous solution of 50  $\mu\text{g}$  of radioactive vitamin B<sub>12</sub> (specific activity, 14.4  $\mu\text{c}/\text{mg}$ ) were mixed with either 10 ml of water or 10 ml of the "elixir"; this "elixir" contained all the components of the "elixir" with vitamin B<sub>12</sub> except vitamin B<sub>12</sub>. Precisely two hours after taking one or the other solution, each patient received 1 ml of a vitamin B<sub>12</sub> solution (1000  $\mu\text{g}/\text{ml}$ ) intramuscularly. A 24-hour urine specimen was collected. (At first, both 2- and 48-hour specimens were collected, but it was found that the 48-hour specimen yielded less than 5 per cent of the vitamin B<sub>12</sub> excreted during the first 24 hours.)

Each specimen was measured by pouring one half of the urine into a beaker containing 50  $\mu\text{g}$  of unlabeled vitamin B<sub>12</sub> as carrier. After evaporation on a steam bath, the contents of the beaker were transferred into a bottle graduated to 50 ml and made up to volume. The bottle was then inserted into the well of a scintillation counter for radioactivity measurement.

*Study Procedure:* The study was conducted over an eight-month period on 60 young, healthy volunteers (ages 22-42) from a penal institution. Four separate trials were made in order to compare the urinary excretion of radioactivity in a number of patients who received radioactive vitamin B<sub>12</sub> plus water, with an equal number who received radioactive vitamin B<sub>12</sub> with the "elixir" (Table I).

In addition, 15 volunteers received both regimens (Table II); 7 of these (Group A)

began on radioactive vitamin B<sub>12</sub> plus water and were switched to radioactive vitamin B<sub>12</sub> plus the "elixir"; 8 (Group B) began on radioactive vitamin B<sub>12</sub> plus the "elixir" and

TABLE I

The Effect of Administration of an Elixir on the Urinary Excretion of Orally Administered Radioactive Vitamin B<sub>12</sub> in Young, Healthy Adults

Study	Average radioactive vitamin B <sub>12</sub> in 24-hr urine samples ( $\mu\text{g}$ )		Statistical significance of the differences
	Controls (25)	Treated group (35)	
I	450 (7)	878 (6)	P < 0.05
II	470 (7)	951 (5)	P < 0.05
III	529 (7)	622 (6)	P < 0.05
IV	546 (4)	753 (6)	P < 0.05
		765 (6)	
		670 (6)	

( ) indicates number of subjects studied.

TABLE II

The Urinary Excretion Test on Radioactive Vitamin B<sub>12</sub> with or without an Elixir by Switchback Experiment

Group	Therapy	Urinary excretion	Difference between (1) and (2)
		$\mu\text{g}$ in 24 hrs	
A (7)	1. 50 $\mu\text{g}$ + water	706 $\pm$ 168	P $\ll$ 0.05
	2. 50 $\mu\text{g}$ + elixir	1680 $\pm$ 110	
B (8)	1. 50 $\mu\text{g}$ + elixir	778 $\pm$ 49	P < 0.05
	2. 50 $\mu\text{g}$ + water	575 $\pm$ 90	

( ) indicates number of subjects studied.

TABLE III

The Effect of an Elixir on Urinary Excretion of Orally Administered Radioactive Vitamin B<sub>12</sub> in Patients with Pernicious Anemia in Remission

Subject	Treatment*	
	2 $\mu\text{g}$ vitamin B <sub>12</sub>	2 $\mu\text{g}$ vitamin B <sub>12</sub> + 30 ml Elixir
A	0.80	1.4
B	0.60	3.0
C	—	0.97
D	0.92	4.1
E	0.8	2.6
F	—	0.9

\* Urinary excretion expressed as per cent of the orally administered radioactive vitamin B<sub>12</sub>.

were then switched to the radioactive vitamin plus water.

Urinary excretion tests were also performed in six subjects who had pernicious anemia in remission (Table III). They were given oral doses of 2  $\mu\text{g}$  of radioactive vitamin B<sub>12</sub> in

30 ml of the "elixir," and then received 1.0 mg of unlabeled vitamin B<sub>12</sub> two hours later by injection.

#### RESULTS

**Serum Level Studies:** The results of the first study (Fig. 1) show that the mean vitamin B<sub>12</sub> serum level in the 21 patients receiving the "elixir" with vitamin B<sub>12</sub> was  $652 \pm 61.7 \mu\mu\text{g/ml}$ . In 139 patients who did not receive the "elixir" with vitamin B<sub>12</sub>, the mean serum level was  $255 \pm 15.8 \mu\mu\text{g/ml}$ . This difference is statistically significant.

It should be pointed out that several patients in the control group took the "elixir" with vitamin B<sub>12</sub> at irregular intervals.\* This fact, however, would only tend to increase the vitamin B<sub>12</sub> serum level of the control group. Undoubtedly, then, the effect of the "elixir" on the vitamin B<sub>12</sub> serum level was marked.

The results of the second study (Fig. 2) demonstrate that it required from six to eight months to replete tissue reserves by the daily oral administration of 100  $\mu\text{g}$  of vitamin B<sub>12</sub>. The mean serum level climbed from 100 to 250  $\mu\mu\text{g/ml}$ . The four subjects (circles) who were continued on a 100- $\mu\text{g}$  vitamin B<sub>12</sub> capsule for two more months experienced only a slight elevation (from 250 to 369  $\mu\mu\text{g/ml}$ ). On the other hand, the four patients (crosses) who were switched from 100  $\mu\text{g}$  of vitamin B<sub>12</sub> alone to 25  $\mu\text{g}$  of vitamin B<sub>12</sub> in the "elixir" experienced a marked increase in serum levels (from 250 to 505  $\mu\mu\text{g/ml}$ ).

The results of the third experiment (Fig. 3) again demonstrated the superiority of the "elixir" with vitamin B<sub>12</sub> (crosses) to vitamin B<sub>12</sub> alone (triangles), as determined by serum levels. The average serum level of those on the "elixir" was 630; of those on vitamin B<sub>12</sub> alone, 275  $\mu\mu\text{g/ml}$ .

The results of four separate trials on 60 young volunteers (Table I) demonstrate that each subject receiving the "elixir" excreted significantly greater amounts of vitamin B<sub>12</sub>

than those who received vitamin B<sub>12</sub> alone. Every patient who received both regimens excreted more vitamin B<sub>12</sub> when taking the "elixir" (Table II). There was, however, considerable variation in the amounts excreted from experiment to experiment.

The results in patients with pernicious anemia (Table III) demonstrate that the "elixir" with vitamin B<sub>12</sub> was of questionable value in increasing their vitamin B<sub>12</sub> absorption. Of the 6 patients in remission, 3 had a partial response only; 3 had a negligible response. Of 3 patients in relapse, 2 responded, but the third did not. However, the latter patient had also failed to respond to any other oral therapy.

#### DISCUSSION

Vitamin B<sub>12</sub> is essential for human nutrition<sup>9,10</sup> and for the treatment of certain diseases. Its use may be broadened as its importance in treating many metabolic disorders becomes better understood; therefore, it is of the utmost importance to find a means of assuring absorption when this vitamin is given orally. Although it is logical to assume that the oral coadministration of intrinsic factor preparations will increase the absorption of vitamin B<sub>12</sub> by healthy individuals, data to support this hypothesis are inconsistent and meager. According to some reports<sup>4,5,6</sup> the use of certain intrinsic factor preparations is contraindicated in individuals without achylia gastrica. In our laboratory we have been interested in obtaining simple chemical substances capable of enhancing the absorption of vitamin B<sub>12</sub>.

It is of particular interest to note that the "elixir" reported on in this paper, which possesses a marked ability to increase vitamin B<sub>12</sub> absorption, is not derived or extracted from the usual animal sources of intrinsic factor. While differences in excretion were demonstrable in each test, the variation among the test subjects was great. This variation is primarily a reflection of our lack of precise knowledge of the mode of action (be it physical or chemical). It is conceivable that the ability of the combination to enhance vitamin B<sub>12</sub> absorption may be due to its physical characteristics; to

\* In an unknown number of instances, subjects in this control group requested this mixture; hence, the average value of the vitamin B<sub>12</sub> serum level in the control group is higher than the mean value of serum obtained from other populations.

some chemical ingredients; or even to a chemical reaction which alters the chemical structure of vitamin B<sub>12</sub> to a form<sup>11</sup> more easily absorbed than is cyanocobalamin.

Intrinsic factor is defined by Castle and associates<sup>12</sup> as a substance present in gastric juice which, when given with vitamin B<sub>12</sub> by mouth, will produce a therapeutic response in pernicious anemia patients. Subsequent study by Schilling<sup>3</sup> showed that it will increase the absorption of vitamin B<sub>12</sub> in such patients, according to the urinary excretion test. Thus, the "elixir" used in our study cannot be classified as an intrinsic factor-like substance unless it can regularly enhance absorption in patients with pernicious anemia. Because of its failure to regularly or markedly increase absorption in patients with pernicious anemia, it is questionable whether this combination itself can be considered to possess intrinsic factor activity. Whether the addition of other substances, such as those which bind vitamin B<sub>12</sub>—a property believed by some to be inherent and essential to intrinsic factor activity—will result in a mixture with true intrinsic factor properties, remains to be answered by further experiments.

#### SUMMARY AND CONCLUSIONS

In order to evaluate the ability of an elixir containing vitamin B<sub>12</sub>, other vitamins, and lipotropic substances to enhance the absorption of vitamin B<sub>12</sub>, several studies were performed. They compared the serum vitamin B<sub>12</sub> levels of subjects receiving the elixir with those receiving vitamin B<sub>12</sub> alone. These studies involved 258 patients (189 old people, 60 young normal volunteers, and 9 patients with pernicious anemia). In the elderly people, vitamin B<sub>12</sub> absorption was evaluated by assays of blood serum; in the volunteers and patients with pernicious anemia, by urinary excretion studies of radioactive vitamin B<sub>12</sub>.

The results of every study on healthy subjects revealed that the elixir was capable of producing significantly higher serum vitamin B<sub>12</sub> levels than could be obtained with larger doses of vitamin B<sub>12</sub> alone. The elixir was of questionable value in treating patients with pernicious anemia.

It is concluded that this elixir is a singularly effective agent for treating vitamin B<sub>12</sub> deficiency not caused by deficiency of intrinsic factor; that it enhances the absorption of B<sub>12</sub>; and that the preparation cannot as yet be considered to have intrinsic factor properties.

#### ACKNOWLEDGMENT

The authors express their appreciation for the faithful services of Miss Alicia Willer.

#### REFERENCES

1. CHOW, B. F., LANG, C. A., DAVIS, R., CONLEY, C. L., and ELLICOTT, C. E.: The appearance of vitamin B<sub>12</sub> activity in urine after oral and intramuscular administration to man. *Bull. Johns Hopkins Hosp.* 87: 156, 1950.
2. WELCH, A. D., SCHARF, V., HEINLE, R. W., and MEACHEM, G. C.: Assay for intrinsic factor in patients with pernicious anemia in remission given radioactive vitamin B<sub>12</sub>. *Fed. Proc.* 11: 308, 1952.
3. SCHILLING, R. F.: Intrinsic factor studies. II. The effect of gastric juice on the urinary excretion of radioactivity. *J. Lab. & Clin. Med.* 42: 860, 1953.
4. SWENDSEID, M. E., HALSTED, J. A., and LIBBY, R. L.: Excretion of cobalt 60-labeled vitamin B<sub>12</sub> after total gastrectomy. *Proc. Soc. Exper. Biol. & Med.* 83: 226, 1953.
5. ROSENBLUM, C., WOODBURY, D. T., GILFILLAN, W. E., and EMERSON, G. A.: Effect of intrinsic factor concentrate upon utilization of orally administered vitamin B<sub>12</sub> by rats. *Proc. Soc. Exper. Biol. & Med.* 87: 268, 1954.
6. CHOW, B. F., WILLIAMS, W. L., OKUDA, K., and GRASBECK, R.: The urinary excretion test for absorption of vitamin B<sub>12</sub>. II. Effect of crude and purified intrinsic factor preparation. *AM. J. CLIN. NUTRITION* 4: 147, 1956.
7. OKUDA, K., WOOD, R. D., LANG, C. A., and CHOW, B. F.: Serum levels of vitamin B<sub>12</sub> in man. *Fed. Proc.* 13: 1546, 1954.
8. CHOW, B. F., OKUDA, K., GILBERT, J. P., and ROSENBLUM, C.: The urinary excretion test for absorption of vitamin B<sub>12</sub>. I. Reproducibility of results and agewise variation. *AM. J. CLIN. NUTRITION* 4: 142, 1956.
9. WOKES, F., BADENOCH, J., and SINCLAIR, H. M.: Human dietary deficiency of vitamin B<sub>12</sub>. *AM. J. CLIN. NUTRITION* 3: 375, 1955.
10. JOLLIFFE, N., FUNARO, R., FRONTALI, G., MAGGIONI, G., CORBO, S., and LANCIANO, G.: Vitamin B<sub>12</sub> as a growth factor in Italian children on diets low in animal protein. *Current Research on Vitamins in Trophology*, Nutrition Symposium Series No. 7, The Natl. Vitamin Foundation, New York, 1953, p. 119.

11. ROSENBLUM, C., WOODBURY, D. T., GILBERT, J. P., OKUDA, K., and CHOW, B. F.: Comparative absorption of vitamin B<sub>12</sub> analogues by normal humans. I. Chlorocobalamin vs. cyanocobalamin. *Proc. Soc. Exper. Biol. & Med.*, 89: 63, 1955.
12. BERK, L., CASTLE, W. B., WELCH, A. D., HEINLE, R. W., ANKER, R., and EPSTEIN, M.: Observations on the etiologic relationship of achylia gastrica to pernicious anemia. X. Activity of vitamin B<sub>12</sub> as food (intrinsic factor). *New England J. Med.* 239: 911, 1948.

